Rivoglitazone
- Generic Name
- Rivoglitazone
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H19N3O4S
- CAS Number
- 185428-18-6
- Unique Ingredient Identifier
- 3A3N0634Q6
- Background
Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes. It is being developed by Daiichi Sankyo Co.
- Associated Conditions
- -
- Associated Therapies
- -
Study of Rivoglitazone in Type 2 Diabetes Mellitus
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-06-08
- Last Posted Date
- 2021-07-27
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 1912
- Registration Number
- NCT00484198
Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 441
- Registration Number
- NCT00143520
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath